Valuation: Rapport Therapeutics, Inc.

Market Cap 2.18B 1.89B 1.76B 1.62B 3.04B 208B 3.09B 20.68B 8.12B 104B 8.2B 8.02B 344B P/E 2026 *
-11.3x
P/E 2027 * -10.2x
Enterprise Value 1.85B 1.6B 1.5B 1.37B 2.58B 176B 2.62B 17.57B 6.89B 88.41B 6.96B 6.81B 292B EV / Sales 2026 *
92.7x
EV / Sales 2027 * -
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day-1.86%
1 week+11.01%
Current month+11.01%
1 month+8.18%
3 months+19.58%
6 months+66.75%
Current year+49.93%
1 week 40.69
Extreme 40.69
48
1 month 38.62
Extreme 38.62
48
Current year 25.21
Extreme 25.21
48
1 year 13.86
Extreme 13.86
48
3 years 6.43
Extreme 6.43
48
5 years 6.43
Extreme 6.43
48
10 years 6.43
Extreme 6.43
48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 2022-12-31
Chief Executive Officer 48 2023-01-31
Director of Finance/CFO 58 2023-10-31
Director TitleAgeSince
Director/Board Member 61 2023-08-22
Director/Board Member 48 2023-02-28
Director/Board Member 54 2022-01-31
Date Insider Type Main position Quantity % Market Cap.
7/27/26 Sell

Chief Executive Officer

-2,210 0.0046%
7/14/26 Sell

Chief Executive Officer

-8,210 0.0172%
6/30/26 Sell

Chief Operating Officer

-10,000 0.0209%
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%+11.01%+212.65% - 2.18B
+0.99%+1.78%+5.07%+17.01% 49.47B
+3.71%+9.40%+486.14%+592.61% 43.97B
+5.60%+10.21%+20.85%+73.63% 39.6B
+2.70%+1.57%+32.71%+9.15% 39.29B
+2.21%+6.75%+20.20%+47.53% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+35.99%+122.50% 16.49B
-0.11%+2.41%+5.03%+20.01% 14.01B
+0.75%+15.04%+79.84%+23.95% 12.77B
Average +1.72%+6.79%+99.83%+113.30% 26.7B
Weighted average by Cap. +2.51%+6.14%+106.07%+138.38%

Financials

2026 *2027 *
Net sales 20M 17.3M 16.16M 14.82M 27.88M 1.9B 28.32M 190M 74.4M 954M 75.1M 73.46M 3.15B -
Net income -192M -166M -155M -142M -267M -18.26B -272M -1.82B -714M -9.15B -720M -705M -30.25B -229M -198M -185M -170M -319M -21.77B -324M -2.17B -851M -10.91B -859M -840M -36.08B
Net Debt -329M -285M -266M -244M -459M -31.32B -466M -3.12B -1.22B -15.7B -1.24B -1.21B -51.9B -477M -412M -385M -353M -664M -45.37B -675M -4.52B -1.77B -22.74B -1.79B -1.75B -75.18B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
26-08-07 US$45.49 -1.86% 246,056
26-08-06 US$46.35 +9.21% 408,370
26-08-05 US$42.44 +0.57% 210,108
26-08-04 US$42.20 +3.46% 398,035
26-08-03 US$40.79 -0.46% 315,229
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
45.49USD
Average target price
59.30USD
Spread / Average Target
+30.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock